# Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

> **NCT01464762** · — · APPROVED_FOR_MARKETING · sponsor: **Janssen Infectious Diseases BVBA**

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** TMC207

## Key facts

- **NCT ID:** NCT01464762
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464762, "Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01464762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*